Novel delivery approaches for cancer therapeutics

Journal of Controlled Release

Volumn 219, Issue , 2015, Pages 248-268

  Mitra, Ashim K ^a   Agrahari, Vibhuti ^a   Mandal, Abhirup ^a   Cholkar, Kishore ^a,b   Natarajan, Chandramouli ^a   Shah, Sujay ^a   Joseph, Mary ^a   Trinh, Hoang M ^a   Vaishya, Ravi ^a,c   Yang, Xiaoyan ^a   Hao, Yi ^a   Khurana, Varun ^c   Pal, Dhananjay ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b RiconPharma LLC   (United States)

^c INSYS Therapeutics Inc   (United States)

Author keywords

Cancer; Cell Penetrating Peptides; Chemotherapeutics; Efflux Pumps; Gene therapy; Immunotherapy; Stem cells; Targeted Drug Delivery; Tumor

Indexed keywords

CELLS; CYTOLOGY; DIAGNOSIS; DRUG THERAPY; GENE THERAPY; GENE TRANSFER; GENES; PHARMACODYNAMICS; RADIOTHERAPY; STEM CELLS; SURGERY; TUMORS; ULTRASONIC APPLICATIONS;

CANCER; CELL-PENETRATING PEPTIDE; CHEMOTHERAPEUTICS; EFFLUX PUMPS; IMMUNOTHERAPY; TARGETED DRUG DELIVERY;

DISEASES;

ABC TRANSPORTER; ADENOVIRUS VECTOR; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; APTAMER; CELL PENETRATING PEPTIDE; DNA TOPOISOMERASE INHIBITOR; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; PRODRUG; RITONAVIR; SMALL INTERFERING RNA; NANOPARTICLE;

ADENO ASSOCIATED VIRUS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER THERAPY; CELL MEMBRANE; CELL NUCLEUS MEMBRANE; DRUG DELIVERY SYSTEM; DRUG RESISTANCE; DRUG TARGETING; ELECTROPORATION; GENE TARGETING; GENE THERAPY; HERPESVIRIDAE; HUMAN; HYDRODYNAMICS; NONHUMAN; PH; PHYSIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; VIRAL GENE THERAPY; ANIMAL; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NANOPARTICLES; NEOPLASMS; PRODRUGS;

EID: 84947235944     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.09.067     Document Type: Article

References (361)

1. J. Liu, Y. Huang, A. Kumar, A. Tan, S. Jin, A. Mozhi, and X.J. Liang pH-sensitive nano-systems for drug delivery in cancer therapy Biotechnol. Adv. 32 2014 693 710
2. R. de la Rica, D. Aili, and M.M. Stevens Enzyme-responsive nanoparticles for drug release and diagnostics Adv. Drug Deliv. Rev. 64 2012 967 978
3. C.E. DeSantis, C.C. Lin, A.B. Mariotto, R.L. Siegel, K.D. Stein, J.L. Kramer, R. Alteri, A.S. Robbins, and A. Jemal Cancer treatment and survivorship statistics CA Cancer J. Clin. 64 2014 2014 252 271
4. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
5. M. Talekar, T.H. Tran, and M. Amiji Translational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory Diseases AAPS J. 17 2015 813 827
6. C. Kandoth, M.D. McLellan, F. Vandin, K. Ye, B. Niu, C. Lu, M. Xie, Q. Zhang, J.F. McMichael, M.A. Wyczalkowski, M.D. Leiserson, C.A. Miller, J.S. Welch, M.J. Walter, M.C. Wendl, T.J. Ley, R.K. Wilson, B.J. Raphael, and L. Ding Mutational landscape and significance across 12 major cancer types Nature 502 2013 333 339
7. SEER Training Modules, Cancer Registration & Surveillance Modules 2015 U. S. National Institutes of Health
8. R.K. Portenoy Postherpetic neuralgia: a workable treatment plan Geriatrics 41 1986 (34-36, 41-33, 47-38)
9. I. Youm, V. Agrahari, J.B. Murowchick, and B.B. Youan Uptake and cytotoxicity of docetaxel-loaded hyaluronic acid-grafted oily core nanocapsules in MDA-MB 231 cancer cells Pharm. Res. 31 2014 2439 2452
10. K. Traynor Ado-trastuzumab emtansine approved for advanced breast cancer Am. J. Health Syst. Pharm. 70 2013 562
11. A. Goncalves, O. Tredan, C. Villanueva, and C. Dumontet Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1) Bull. Cancer 99 2012 1183 1191
12. B.A. Teicher, and J.H. Doroshow The promise of antibody-drug conjugates N. Engl. J. Med. 367 2012 1847 1848
13. S.M. Ansell Brentuximab vedotin Blood 124 2014 3197 3200
14. B. Pro, R. Advani, P. Brice, N.L. Bartlett, J.D. Rosenblatt, T. Illidge, J. Matous, R. Ramchandren, M. Fanale, J.M. Connors, Y. Yang, E.L. Sievers, D.A. Kennedy, and A. Shustov Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 30 2012 2190 2196
15. E.D. Jacobsen, J.P. Sharman, Y. Oki, R.H. Advani, J.N. Winter, C.M. Bello, G. Spitzer, M.C. Palanca-Wessels, D.A. Kennedy, P. Levine, J. Yang, and N.L. Bartlett Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression Blood 125 2015 1394 1402
16. S.M. Nimjee, C.P. Rusconi, and B.A. Sullenger Aptamers: an emerging class of therapeutics Annu. Rev. Med. 56 2005 555 583
17. D.H. Bunka, and P.G. Stockley Aptamers come of age - at last Nat. Rev. Microbiol. 4 2006 588 596
18. Y.H. Lao, K.K. Phua, and K.W. Leong Aptamer nanomedicine for cancer therapeutics: barriers and potential for translation ACS Nano 9 2015 2235 2254
19. H. Hu, A. Dai, J. Sun, X. Li, F. Gao, L. Wu, Y. Fang, H. Yang, L. An, H. Wu, and S. Yang Aptamer-conjugated Mn3O4@SiO2 core-shell nanoprobes for targeted magnetic resonance imaging Nanoscale 5 2013 10447 10454
20. F. Radom, P.M. Jurek, M.P. Mazurek, J. Otlewski, and F. Jelen Aptamers: molecules of great potential Biotechnol. Adv. 31 2013 1260 1274
21. L. Meng, L. Yang, X. Zhao, L. Zhang, H. Zhu, C. Liu, and W. Tan Targeted delivery of chemotherapy agents using a liver cancer-specific aptamer PLoS One 7 2012 e33434
22. D. Shangguan, L. Meng, Z.C. Cao, Z. Xiao, X. Fang, Y. Li, D. Cardona, R.P. Witek, C. Liu, and W. Tan Identification of liver cancer-specific aptamers using whole live cells Anal. Chem. 80 2008 721 728
23. H.Y. Cao, A.H. Yuan, W. Chen, X.S. Shi, and Y. Miao A DNA aptamer with high affinity and specificity for molecular recognition and targeting therapy of gastric cancer BMC Cancer 14 2014 699
24. H.Y. Kong, and J. Byun Screening and characterization of a novel RNA aptamer that specifically binds to human prostatic acid phosphatase and human prostate cancer cells Mol. Cell 38 2015 171 179
25. X.W. He, T. Liu, Y.X. Chen, D.J. Cheng, X.R. Li, Y. Xiao, and Y.L. Feng Calcium carbonate nanoparticle delivering vascular endothelial growth factor-C siRNA effectively inhibits lymphangiogenesis and growth of gastric cancer in vivo Cancer Gene Ther. 15 2008 193 202
26. Y. Wang, Z. Xu, S. Guo, L. Zhang, A. Sharma, G.P. Robertson, and L. Huang Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis Mol. Ther. 21 2013 1919 1929
27. L. Wang, Y. Hao, H. Li, Y. Zhao, D. Meng, D. Li, J. Shi, H. Zhang, Z. Zhang, and Y. Zhang Co-delivery of doxorubicin and siRNA for glioma therapy by a brain targeting system: angiopep-2-modified poly(lactic-co-glycolic acid) nanoparticles J. Drug Target. 2015 1 15
28. D.B. Jacoby, E. Dyskin, M. Yalcin, K. Kesavan, W. Dahlberg, J. Ratliff, E.W. Johnson, and S.A. Mousa Potent pleiotropic anti-angiogenic effects of TM601, a synthetic chlorotoxin peptide Anticancer Res. 30 2010 39 46
29. I. Rjeibi, K. Mabrouk, H. Mosrati, C. Berenguer, H. Mejdoub, C. Villard, D. Laffitte, D. Bertin, L. Ouafik, J. Luis, M. Elayeb, and N. Srairi-Abid Purification, synthesis and characterization of AaCtx, the first chlorotoxin-like peptide from Androctonus australis scorpion venom Peptides 32 2011 656 663
30. M.J. McGuire, B.P. Gray, S. Li, D. Cupka, L.A. Byers, L. Wu, S. Rezaie, Y.H. Liu, N. Pattisapu, J. Issac, T. Oyama, L. Diao, J.V. Heymach, X.J. Xie, J.D. Minna, and K.C. Brown Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer Sci. Report. 4 2014 4480
31. X.Y. Zhang, and W.Y. Lu Recent advances in lymphatic targeted drug delivery system for tumor metastasis Cancer Biol. Med. 11 2014 247 254
32. N. Bertrand, J. Wu, X. Xu, N. Kamaly, and O.C. Farokhzad Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology Adv. Drug Deliv. Rev. 66 2014 2 25
33. Y.H. Bae, and K. Park Targeted drug delivery to tumors: myths, reality and possibility J. Control. Release 153 2011 198 205
34. S. Wang, R. Noberini, J.L. Stebbins, S. Das, Z. Zhang, B. Wu, S. Mitra, S. Billet, A. Fernandez, N.A. Bhowmick, S. Kitada, E.B. Pasquale, P.B. Fisher, and M. Pellecchia Targeted delivery of paclitaxel to EphA2-expressing cancer cells Clin. Cancer Res. 19 2013 128 137
35. W. Gao, B. Xiang, T.T. Meng, F. Liu, and X.R. Qi Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides Biomaterials 34 2013 4137 4149
36. P.M.F. Tarek, M. Fahmy, A. Goyal, and W. Mark Saltzman Targeted for drug delivery Mater. Today 8 2005 18 26
37. F. Alexis, E. Pridgen, L.K. Molnar, and O.C. Farokhzad Factors affecting the clearance and biodistribution of polymeric nanoparticles Mol. Pharm. 5 2008 505 515
38. S.D. Perrault, C. Walkey, T. Jennings, H.C. Fischer, and W.C. Chan Mediating tumor targeting efficiency of nanoparticles through design Nano Lett. 9 2009 1909 1915
39. J. Regberg, A. Srimanee, and U. Langel Applications of cell-penetrating peptides for tumor targeting and future cancer therapies Pharmaceuticals 5 2012 991 1007
40. M. Lelle, S.U. Frick, K. Steinbrink, and K. Peneva Novel cleavable cell-penetrating peptide-drug conjugates: synthesis and characterization J. Pept. Sci. 20 2014 323 333
41. M. Soler, M. Gonzalez-Bartulos, E. Figueras, X. Ribas, M. Costas, A. Massaguer, M. Planas, and L. Feliu Enzyme-triggered delivery of chlorambucil from conjugates based on the cell-penetrating peptide BP16 Org. Biomol. Chem. 13 2015 1470 1480
42. G. Alvisi, I.K. Poon, and D.A. Jans Tumor-specific nuclear targeting: promises for anti-cancer therapy? Drug Resist. Updat. 9 2006 40 50
43. J.G. Turner, and D.M. Sullivan CRM1-mediated nuclear export of proteins and drug resistance in cancer Curr. Med. Chem. 15 2008 2648 2655
44. M. Sui, W. Liu, and Y. Shen Nuclear drug delivery for cancer chemotherapy J. Control. Release 155 2011 227 236
45. K.M. Wagstaff, J.Y. Fan, M.A. De Jesus, D.J. Tremethick, and D.A. Jans Efficient gene delivery using reconstituted chromatin enhanced for nuclear targeting FASEB J. 22 2008 2232 2242
46. Y. Nakamura, C. Martin, K. Krapcho, and R. White Isolation and mapping of a polymorphic DNA sequence (pCMM8.1) on chromosome 1p [D1S63] Nucleic Acids Res. 16 1988 9370
47. U. Lahtinen, M. Honsho, R.G. Parton, K. Simons, and P. Verkade Involvement of caveolin-2 in caveolar biogenesis in MDCK cells FEBS Lett. 538 2003 85 88
48. O. Harush-Frenkel, N. Debotton, S. Benita, and Y. Altschuler Targeting of nanoparticles to the clathrin-mediated endocytic pathway Biochem. Biophys. Res. Commun. 353 2007 26 32
49. O. Harush-Frenkel, E. Rozentur, S. Benita, and Y. Altschuler Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells Biomacromolecules 9 2008 435 443
50. A. Harel, and D.J. Forbes Importin beta: conducting a much larger cellular symphony Mol. Cell 16 2004 319 330
51. K.J. Ryan, and S.R. Wente The nuclear pore complex: a protein machine bridging the nucleus and cytoplasm Curr. Opin. Cell Biol. 12 2000 361 371
52. K. Ribbeck, and D. Gorlich Kinetic analysis of translocation through nuclear pore complexes EMBO J. 20 2001 1320 1330
53. D. Mohr, S. Frey, T. Fischer, T. Guttler, and D. Gorlich Characterisation of the passive permeability barrier of nuclear pore complexes EMBO J. 28 2009 2541 2553
54. W. Wei, G.H. Ma, G. Hu, D. Yu, T. McLeish, Z.G. Su, and Z.Y. Shen Preparation of hierarchical hollow CaCO3 particles and the application as anticancer drug carrier J. Am. Chem. Soc. 130 2008 15808 15810
55. M. Tagliazucchi, O. Peleg, M. Kroger, Y. Rabin, and I. Szleifer Effect of charge, hydrophobicity, and sequence of nucleoporins on the translocation of model particles through the nuclear pore complex Proc. Natl. Acad. Sci. U. S. A. 110 2013 3363 3368
56. S.R. Schwarze, A. Ho, A. Vocero-Akbani, and S.F. Dowdy In vivo protein transduction: delivery of a biologically active protein into the mouse Science 285 1999 1569 1572
57. D. Sarko, B. Beijer, R. Garcia Boy, E.M. Nothelfer, K. Leotta, M. Eisenhut, A. Altmann, U. Haberkorn, and W. Mier The pharmacokinetics of cell-penetrating peptides Mol. Pharm. 7 2010 2224 2231
58. B. Hoang, S.N. Ekdawi, R.M. Reilly, and C. Allen Active targeting of block copolymer micelles with trastuzumab Fab fragments and nuclear localization signal leads to increased tumor uptake and nuclear localization in HER2-overexpressing xenografts Mol. Pharm. 10 2013 4229 4241
59. W. Yuan, R. Kuai, R. Ran, L. Fu, Y. Yang, Y. Qin, Y. Liu, J. Tang, H. Fu, Q. Zhang, M. Yuan, Z. Zhang, F. Gao, and Q. He Increased delivery of doxorubicin into tumor cells using extracellularly activated TAT functionalized liposomes: in vitro and in vivo study J. Biomed. Nanotechnol. 10 2014 1563 1573
60. J.Y. Zhu, Q. Lei, B. Yang, H.Z. Jia, W.X. Qiu, X. Wang, X. Zeng, R.X. Zhuo, J. Feng, and X.Z. Zhang Efficient nuclear drug translocation and improved drug efficacy mediated by acidity-responsive boronate-linked dextran/cholesterol nanoassembly Biomaterials 52 2015 281 290
61. L.P. Swift, A. Rephaeli, A. Nudelman, D.R. Phillips, and S.M. Cutts Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death Cancer Res. 66 2006 4863 4871
62. C. Wang, C. Wu, X. Zhou, T. Han, X. Xin, J. Wu, J. Zhang, and S. Guo Enhancing cell nucleus accumulation and DNA cleavage activity of anti-cancer drug via graphene quantum dots Sci. Report. 3 2013 2852
63. R. Misra, and S.K. Sahoo Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy Eur. J. Pharm. Sci. 39 2010 152 163
64. O. Aronov, A.T. Horowitz, A. Gabizon, M.A. Fuertes, J.M. Perez, and D. Gibson Nuclear localization signal-targeted poly(ethylene glycol) conjugates as potential carriers and nuclear localizing agents for carboplatin analogues Bioconjug. Chem. 15 2004 814 823
65. E.S. Lee, Z. Gao, D. Kim, K. Park, I.C. Kwon, and Y.H. Bae Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance J. Control. Release 129 2008 228 236
66. Y. Shen, Z. Zhou, M. Sui, J. Tang, P. Xu, E.A. Van Kirk, W.J. Murdoch, M. Fan, and M. Radosz Charge-reversal polyamidoamine dendrimer for cascade nuclear drug delivery Nanomedicine 5 2010 1205 1217
67. P. Xu, E.A. Van Kirk, Y. Zhan, W.J. Murdoch, M. Radosz, and Y. Shen Targeted charge-reversal nanoparticles for nuclear drug delivery Angew. Chem. 46 2007 4999 5002
68. S. Cao, A. Cripps, and M.Q. Wei New strategies for cancer gene therapy: progress and opportunities Clin. Exp. Pharmacol. Physiol. 37 2010 108 114
69. R. Alexandrova Experimental strategies in gene therapy of cancer J. BUON 14 Suppl. 1 2009 S23 S32
70. E.V. Koonin, T.G. Senkevich, and V.V. Dolja The ancient Virus World and evolution of cells Biol. Direct 1 2006 29
71. D. Ibraheem, A. Elaissari, and H. Fessi Gene therapy and DNA delivery systems Int. J. Pharm. 459 2014 70 83
72. M.G. Castro, M. Candolfi, T.J. Wilson, A. Calinescu, C. Paran, N. Kamran, C. Koschmann, M.A. Moreno-Ayala, H. Assi, and P.R. Lowenstein Adenoviral vector-mediated gene therapy for gliomas: coming of age Expert. Opin. Biol. Ther. 14 2014 1241 1257
73. T. Fukazawa, J. Matsuoka, T. Yamatsuji, Y. Maeda, M.L. Durbin, and Y. Naomoto Adenovirus-mediated cancer gene therapy and virotherapy (Review) Int. J. Mol. Med. 25 2010 3 10
74. X. Yao, Y. Yoshioka, T. Morishige, Y. Eto, H. Watanabe, Y. Okada, H. Mizuguchi, Y. Mukai, N. Okada, and S. Nakagawa Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis Gene Ther. 16 2009 1395 1404
75. X. Yao, Y. Yoshioka, T. Morishige, Y. Eto, S. Narimatsu, Y. Kawai, H. Mizuguchi, J.Q. Gao, Y. Mukai, N. Okada, and S. Nakagawa Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy Mol. Ther. 19 2011 1619 1625
76. G. Ma, H. Shimada, K. Hiroshima, Y. Tada, N. Suzuki, and M. Tagawa Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China Drug Des. Devel. Ther. 2 2009 115 122
77. J. Luo, Y. Luo, J. Sun, Y. Zhou, Y. Zhang, and X. Yang Adeno-associated virus-mediated cancer gene therapy: current status Cancer Lett. 356 2015 347 356
78. T.L. Chiu, C.W. Peng, and M.J. Wang Enhanced anti-glioblastoma activity of microglia by AAV2-mediated IL-12 through TRAIL and phagocytosis in vitro Oncol. Rep. 25 2011 1373 1380
79. T. Han, U.M. Abdel-Motal, D.K. Chang, J. Sui, A. Muvaffak, J. Campbell, Q. Zhu, T.S. Kupper, and W.A. Marasco Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma PLoS One 7 2012 e44455
80. J. Pan, Q. Zhang, J. Zhou, D. Ma, X. Xiao, and D.W. Wang Recombinant adeno-associated virus encoding Epstein-Barr virus latent membrane proteins fused with heat shock protein as a potential vaccine for nasopharyngeal carcinoma Mol. Cancer Ther. 8 2009 2754 2761
81. S.S. He, H.S. Shi, T. Yin, Y.X. Li, S.T. Luo, Q.J. Wu, L. Lu, Y.Q. Wei, and L. Yang AAV-mediated gene transfer of human pigment epithelium-derived factor inhibits Lewis lung carcinoma growth in mice Oncol. Rep. 27 2012 1142 1148
82. L. Di, Y. Zhu, J. Jia, J. Yu, G. Song, J. Zhang, L. Che, H. Yang, Y. Han, B. Ma, C. Zhang, Y. Yuan, M. You, F. Wan, X. Wang, X. Zhou, and J. Ren Clinical safety of induced CTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients Clin. Transl. Oncol. 14 2012 675 681
83. Y. Xie, M.J. Hicks, S.M. Kaminsky, M.A. Moore, R.G. Crystal, and A. Rafii AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer Gynecol. Oncol. 135 2014 325 332
84. S. Alam, B.S. Bowser, M. Israr, M.J. Conway, and C. Meyers Adeno-associated virus type 2 infection of nude mouse human breast cancer xenograft induces necrotic death and inhibits tumor growth Cancer Biol. Ther. 15 2014 1013 1028
85. S. Yla-Herttuala Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union Mol. Ther. 20 2012 1831 1832
86. B.J. Passer, T. Cheema, S. Wu, C.L. Wu, S.D. Rabkin, and R.L. Martuza Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models Cancer Gene Ther. 20 2013 17 24
87. W.G. Zeng, J.J. Li, P. Hu, L. Lei, J.N. Wang, and R.B. Liu An oncolytic herpes simplex virus vector, G47Delta, synergizes with paclitaxel in the treatment of breast cancer Oncol. Rep. 29 2013 2355 2361
88. F. Goshima, S. Esaki, C. Luo, M. Kamakura, H. Kimura, and Y. Nishiyama Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer Int. J. Cancer 134 2014 2865 2877
89. K. Breckpot, J.L. Aerts, and K. Thielemans Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics Gene Ther. 14 2007 847 862
90. W. Wang, H. Zhu, H. Zhang, L. Zhang, Q. Ding, H. Jiang, Targeting PPM1D by lentivirus-mediated RNA interference inhibits the tumorigenicity of bladder cancer cells, Braz. J. Med. Biol. Res. = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica... [et al.], 47 (2014) 1044-1049.
91. Z.D. Zhang, Y. Li, Q. Fan, B. Zhao, B. Tan, and X.F. Zhao Annexin A2 is implicated in multi-drug-resistance in gastric cancer through p38MAPK and AKT pathway Neoplasma 61 2014 627 637
92. C. Zhang, Y. Chen, M. Wang, X. Chen, Y. Li, E. Song, X. Liu, S. Kim, and H. Peng PPM1D silencing by RNA interference inhibits the proliferation of lung cancer cells World J. Surg. Oncol. 12 2014 258
93. H. Yin, Z. Yan, Y. Liang, B. Liu, and Q. Su Knockdown of protein phosphatase magnesium-dependent 1 (PPM1D) through lentivirus-mediated RNA silencing inhibits colorectal carcinoma cell proliferation Technol. Cancer Res. Treat. 12 2013 537 543
94. H. Yin, R.L. Kanasty, A.A. Eltoukhy, A.J. Vegas, J.R. Dorkin, and D.G. Anderson Non-viral vectors for gene-based therapy Nat. Rev. Genet. 15 2014 541 555
95. X. Guo, and L. Huang Recent advances in nonviral vectors for gene delivery Acc. Chem. Res. 45 2012 971 979
96. D. Fioretti, S. Iurescia, and M. Rinaldi Recent advances in design of immunogenic and effective naked DNA vaccines against cancer Recent Pat. Anticancer Drug Discov. 9 2014 66 82
97. A. Pharmaceuticals Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) ClinicalTrials.gov [Internet] 2000 National Library of Medicine (US) Bethesda (MD) [cited 2015 July 13]
98. Q. Pharmaceuticals I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation ClinicalTrials.gov [Internet] 2000 National Library of Medicine (US) Bethesda (MD) [cited 2015 July 13]
99. O. Mazda, and T. Kishida Molecular therapeutics of cancer by means of electroporation-based transfer of siRNAs and EBV-based expression vectors Front. Biosci. 1 2009 316 331
100. M.L. Yarmush, A. Golberg, G. Sersa, T. Kotnik, and D. Miklavcic Electroporation-based technologies for medicine: principles, applications, and challenges Annu. Rev. Biomed. Eng. 16 2014 295 320
101. R. Heller, and L.C. Heller Gene electrotransfer clinical trials Adv. Genet. 89 2015 235 262
102. M. Bosnjak, L. Prosen, T. Dolinsek, T. Blagus, B. Markelc, M. Cemazar, C. Bouquet, and G. Sersa Biological properties of melanoma and endothelial cells after plasmid AMEP gene electrotransfer depend on integrin quantity on cells J. Membr. Biol. 246 2013 803 819
103. A.I. Daud, R.C. DeConti, S. Andrews, P. Urbas, A.I. Riker, V.K. Sondak, P.N. Munster, D.M. Sullivan, K.E. Ugen, J.L. Messina, and R. Heller Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 26 2008 5896 5903
104. E. Cha, and A. Daud Plasmid IL-12 electroporation in melanoma Hum. Vaccin. Immunother. 8 2012 1734 1738
105. Y. Sun, S. Peng, J. Qiu, J. Miao, B. Yang, J. Jeang, C.F. Hung, and T.C. Wu Intravaginal HPV DNA vaccination with electroporation induces local CD8 + T-cell immune responses and antitumor effects against cervicovaginal tumors Gene Ther. 22 2015 528 535
106. B. Bonamassa, L. Hai, and D. Liu Hydrodynamic gene delivery and its applications in pharmaceutical research Pharm. Res. 28 2011 694 701
107. H. Herweijer, and J.A. Wolff Gene therapy progress and prospects: hydrodynamic gene delivery Gene Ther. 14 2007 99 107
108. H. Yazawa, T. Murakami, H.M. Li, T. Back, K. Kurosaka, Y. Suzuki, L. Shorts, Y. Akiyama, K. Maruyama, E. Parsoneault, R.H. Wiltrout, and M. Watanabe Hydrodynamics-based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively suppresses the growth of pre-existing tumors Cancer Gene Ther. 13 2006 993 1001
109. Y. Zhang, H. Li, J. Sun, J. Gao, W. Liu, B. Li, Y. Guo, and J. Chen DC-Chol/DOPE cationic liposomes: a comparative study of the influence factors on plasmid pDNA and siRNA gene delivery Int. J. Pharm. 390 2010 198 207
110. F. Qin, Y. Zhou, J. Shi, and Y. Zhang A DNA transporter based on mesoporous silica nanospheres mediated with polycation poly(allylamine hydrochloride) coating on mesopore surface J. Biomed. Mater. Res. A 90 2009 333 338
111. H.Y. Qureshi, R. Ahmad, and M. Zafarullah High-efficiency transfection of nucleic acids by the modified calcium phosphate precipitation method in chondrocytes Anal. Biochem. 382 2008 138 140
112. W. Lu, G. Zhang, R. Zhang, L.G. Flores 2nd, Q. Huang, J.G. Gelovani, and C. Li Tumor site-specific silencing of NF-kappaB p65 by targeted hollow gold nanosphere-mediated photothermal transfection Cancer Res. 70 2010 3177 3188
113. P. Saccardo, A. Villaverde, and N. Gonzalez-Montalban Peptide-mediated DNA condensation for non-viral gene therapy Biotechnol. Adv. 27 2009 432 438
114. S. Fang, L. Wu, M. Li, H. Yi, G. Gao, Z. Sheng, P. Gong, Y. Ma, and L. Cai ZEB1 knockdown mediated using polypeptide cationic micelles inhibits metastasis and effects sensitization to a chemotherapeutic drug for cancer therapy Nanoscale 6 2014 10084 10094
115. S. Ikegami, K. Yamakami, T. Ono, M. Sato, S. Suzuki, I. Yoshimura, T. Asano, M. Hayakawa, and T. Tadakuma Targeting gene therapy for prostate cancer cells by liposomes complexed with anti-prostate-specific membrane antigen monoclonal antibody Hum. Gene Ther. 17 2006 997 1005
116. P.M. Costa, A.L. Cardoso, L.S. Mendonca, A. Serani, C. Custodia, M. Conceicao, S. Simoes, J.N. Moreira, L. Pereira de Almeida, and M.C. Pedroso de Lima Tumor-targeted Chlorotoxin-coupled Nanoparticles for Nucleic Acid Delivery to Glioblastoma Cells: A Promising System for Glioblastoma Treatment Mol. Ther. 2 2013 e100
117. P.M. Costa, A.L. Cardoso, C. Custodia, P. Cunha, L. Pereira de Almeida, and M.C. Pedroso de Lima MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma J. Control. Release 207 2015 31 39
118. Y. Chen, X. Wang, T. Liu, D.S. Zhang, Y. Wang, H. Gu, and W. Di Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy Int. J. Nanomedicine 10 2015 2579 2594
119. Y. Chen, H. Gu, D.S. Zhang, F. Li, T. Liu, and W. Xia Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier Biomaterials 35 2014 10058 10069
120. H. Yang, Y. Li, T. Li, M. Xu, Y. Chen, C. Wu, X. Dang, and Y. Liu Multifunctional core/shell nanoparticles cross-linked polyetherimide-folic acid as efficient Notch-1 siRNA carrier for targeted killing of breast cancer Sci. Report. 4 2014 7072
121. A. Ekin, O.F. Karatas, M. Culha, and M. Ozen Designing a gold nanoparticle-based nanocarrier for microRNA transfection into the prostate and breast cancer cells J. Gene Med. 16 2014 331 335
122. H.J. Kim, H. Takemoto, Y. Yi, M. Zheng, Y. Maeda, H. Chaya, K. Hayashi, P. Mi, F. Pittella, R.J. Christie, K. Toh, Y. Matsumoto, N. Nishiyama, K. Miyata, and K. Kataoka Precise engineering of siRNA delivery vehicles to tumors using polyion complexes and gold nanoparticles ACS Nano 8 2014 8979 8991
123. M. Mitra, M. Kandalam, J. Rangasamy, B. Shankar, U.K. Maheswari, S. Swaminathan, and S. Krishnakumar Novel epithelial cell adhesion molecule antibody conjugated polyethyleneimine-capped gold nanoparticles for enhanced and targeted small interfering RNA delivery to retinoblastoma cells Mol. Vis. 19 2013 1029 1038
124. M.H. Ki, J.E. Kim, Y.N. Lee, S.M. Noh, S.W. An, H.J. Cho, and D.D. Kim Chitosan-based hybrid nanocomplex for siRNA delivery and its application for cancer therapy Pharm. Res. 31 2014 3323 3334
125. T.S. Li, T. Yawata, and K. Honke Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy Eur. J. Pharm. Sci. 52 2014 48 61
126. S. Ganesh, A.K. Iyer, D.V. Morrissey, and M.M. Amiji Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors Biomaterials 34 2013 3489 3502
127. K. Chen, Y.H. Huang, and J.L. Chen Understanding and targeting cancer stem cells: therapeutic implications and challenges Acta Pharmacol. Sin. 34 2013 732 740
128. S. Kunnimalaiyaan, J. Trevino, S. Tsai, T.C. Gamblin, and M. Kunnimalaiyaan Xanthohumol-Mediated Suppression of Notch1 Signaling Is Associated with Antitumor Activity in Human Pancreatic Cancer Cells Mol. Cancer Ther. 14 2015 1395 1403
129. M.A. Ihle, M. Trautmann, H. Kuenstlinger, S. Huss, C. Heydt, J. Fassunke, E. Wardelmann, S. Bauer, H.U. Schildhaus, R. Buettner, and S. Merkelbach-Bruse miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours Mol. Oncol. 2015
130. C.M. Ho-Yen, J.L. Jones, and S. Kermorgant The clinical and functional significance of c-Met in breast cancer: a review Breast Cancer Res. 17 2015 52
131. B. Brinkhof, H.T. van Tol, M.J. Groot Koerkamp, F.M. Riemers, S.G. I.J, K. Mashayekhi, H.P. Haagsman, and B.A. Roelen A mRNA landscape of bovine embryos after standard and MAPK-inhibited culture conditions: a comparative analysis BMC Genomics 16 2015 277
132. E. Zoni, G. van der Pluijm, P.C. Gray, and M. Kruithof-de Julio Epithelial Plasticity in Cancer: Unmasking a MicroRNA Network for TGF-beta-, Notch-, and Wnt-Mediated EMT J. Oncol. 2015 2015 198967
133. A.R. Noort, K.P. van Zoest, E.M. Weijers, P. Koolwijk, C.X. Maracle, D.V. Novack, M.J. Siemerink, R.O. Schlingemann, P.P. Tak, and S.W. Tas NF-kappaB-inducing kinase is a key regulator of inflammation-induced and tumour-associated angiogenesis J. Pathol. 234 2014 375 385
134. N. Takebe, L. Miele, P.J. Harris, W. Jeong, H. Bando, M. Kahn, S.X. Yang, and S.P. Ivy Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update Nat. Rev. Clin. Oncol. 2015
135. A.N. Khan, N. Kolomeyevskaya, K.L. Singel, M.J. Grimm, K.B. Moysich, S. Daudi, K.S. Grzankowski, S. Lele, L. Ylagan, G.A. Webster, S.I. Abrams, K. Odunsi, and B.H. Segal Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer Oncotarget 6 2015 11310 11326
136. P. Msaouel, J.N. Galeas, A.R. Boiles, R.R. Ruiz, and M. Koutsilieris Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer Curr. Drug Targets 2015
137. Z. Wang, Z. Li, Y. Wang, D. Cao, X. Wang, M. Jiang, M. Li, X. Yan, Y. Li, Y. Liu, and F. Luo Versican silencing improves the antitumor efficacy of endostatin by alleviating its induced inflammatory and immunosuppressive changes in the tumor microenvironment Oncol. Rep. 33 2015 2981 2991
138. M.K. Kashyap, D. Kumar, R. Villa, J.J. La Clair, C. Benner, R. Sasik, H. Jones, E.M. Ghia, L.Z. Rassenti, T.J. Kipps, M.D. Burkart, and J.E. Castro Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B Haematologica 100 2015 945 954
139. A. Martner, H.G. Wiktorin, B. Lenox, F. Ewald Sander, E. Aydin, J. Aurelius, F.B. Thoren, A. Stahlberg, S. Hermodsson, and K. Hellstrand Histamine promotes the development of monocyte-derived dendritic cells and reduces tumor growth by targeting the myeloid NADPH oxidase J. Immunol. 194 2015 5014 5021
140. C.G. Drake, E.J. Lipson, and J.R. Brahmer Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer Nat. Rev. Clin. Oncol. 11 2014 24 37
141. J.N. Blattman, and P.D. Greenberg Cancer immunotherapy: a treatment for the masses Science 305 2004 200 205
142. M. Schuster, A. Nechansky, and R. Kircheis Cancer immunotherapy Biotechnol. J. 1 2006 138 147
143. J.L. Perez-Gracia, S. Labiano, M.E. Rodriguez-Ruiz, M.F. Sanmamed, and I. Melero Orchestrating immune check-point blockade for cancer immunotherapy in combinations Curr. Opin. Immunol. 27 2014 89 97
144. A.S. Hoffman «Intelligent» polymers in medicine and biotechnology Artif. Organs 19 1995 458 467
145. D. Xu, L. Wang, D. Gourevich, E. Kabha, F. Arditti, M. Athamna, S. Cochran, A. Melzer, and J.M. Gnaim Synthesis and inclusion study of a novel gamma-cyclodextrin derivative as a potential thermo-sensitive carrier for doxorubicin Chem. Pharm. Bull. 62 2014 627 635
146. A.S. Wadajkar, Z. Bhavsar, C.Y. Ko, B. Koppolu, W. Cui, L. Tang, and K.T. Nguyen Multifunctional particles for melanoma-targeted drug delivery Acta Biomater. 8 2012 2996 3004
147. D.H. Kim, Y. Guo, Z. Zhang, D. Procissi, J. Nicolai, R.A. Omary, and A.C. Larson Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia Adv. Healthcare Mater. 3 2014 714 724
148. V. Agrahari, C. Zhang, T. Zhang, W. Li, T.K. Gounev, N.A. Oyler, and B.B. Youan Hyaluronidase-sensitive nanoparticle templates for triggered release of HIV/AIDS microbicide in vitro AAPS J. 16 2014 181 193
149. T.L. Andresen, S.S. Jensen, and K. Jorgensen Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release Prog. Lipid Res. 44 2005 68 97
150. C. Minelli, S.B. Lowe, and M.M. Stevens Engineering nanocomposite materials for cancer therapy Small 6 2010 2336 2357
151. C. Nazli, G.S. Demirer, Y. Yar, H.Y. Acar, and S. Kizilel Targeted delivery of doxorubicin into tumor cells via MMP-sensitive PEG hydrogel-coated magnetic iron oxide nanoparticles (MIONPs) Colloids Surf. B: Biointerfaces 122 2014 674 683
152. K. Engin, D.B. Leeper, J.R. Cater, A.J. Thistlethwaite, L. Tupchong, and J.D. McFarlane Extracellular pH distribution in human tumours Int. J. Hyperth. 11 1995 211 216
153. M. Stubbs, P.M. McSheehy, J.R. Griffiths, and C.L. Bashford Causes and consequences of tumour acidity and implications for treatment Mol. Med. Today 6 2000 15 19
154. M.A. Stuart, W.T. Huck, J. Genzer, M. Muller, C. Ober, M. Stamm, G.B. Sukhorukov, I. Szleifer, V.V. Tsukruk, M. Urban, F. Winnik, S. Zauscher, I. Luzinov, and S. Minko Emerging applications of stimuli-responsive polymer materials Nat. Mater. 9 2010 101 113
155. J. Liu, H. Ma, T. Wei, and X.J. Liang CO2 gas induced drug release from pH-sensitive liposome to circumvent doxorubicin resistant cells Chem. Commun. 48 2012 4869 4871
156. Y. Han, W. Chen, Y. Kuang, H. Sun, Z. Wang, and X. Peng UV-Induced DNA Interstrand Cross-Linking and Direct Strand Breaks from a New Type of Binitroimidazole Analogue Chem. Res. Toxicol. 28 2015 919 926
157. C. Skarbek, L.L. Lesueur, H. Chapuis, A. Deroussent, C. Pioche Durieu, A. Daville, J. Caron, M. Rivard, T. Martens, J.R. Bertrand, E. Le Cam, G. Vassal, P. Couvreur, D. Desmaele, and A. Paci Preactivated oxazaphosphorines designed for isophosphoramide mustard delivery as bulk form or nanoassemblies: synthesis and proof of concept J. Med. Chem. 58 2015 705 717
158. K.M. Johnson, Z.D. Parsons, C.L. Barnes, and K.S. Gates Toward hypoxia-selective DNA-alkylating agents built by grafting nitrogen mustards onto the bioreductively activated, hypoxia-selective DNA-oxidizing agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine) J. Organomet. Chem. 79 2014 7520 7531
159. W. Chen, K. Balakrishnan, Y. Kuang, Y. Han, M. Fu, V. Gandhi, and X. Peng Reactive oxygen species (ROS) inducible DNA cross-linking agents and their effect on cancer cells and normal lymphocytes J. Med. Chem. 57 2014 4498 4510
160. S. Cao, Y. Wang, and X. Peng The leaving group strongly affects H(2)O(2)-induced DNA cross-linking by arylboronates J. Organomet. Chem. 79 2014 501 508
161. S. Cao, R. Christiansen, and X. Peng Substituent effects on oxidation-induced formation of quinone methides from arylboronic ester precursors Chemistry 19 2013 9050 9058
162. S. Strese, M. Wickstrom, P.F. Fuchs, M. Fryknas, P. Gerwins, T. Dale, R. Larsson, and J. Gullbo The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo Biochem. Pharmacol. 86 2013 888 895
163. J. Cytarska, K. Misiura, B. Filip-Psurska, and J. Wietrzyk Acyloxymethyl esters of isophosphoramide mustard as new anticancer prodrugs Acta Pol. Pharm. 70 2013 481 487
164. A.L. Wolfe, K.K. Duncan, N.K. Parelkar, D. Brown, G.A. Vielhauer, and D.L. Boger Efficacious cyclic N-acyl O-amino phenol duocarmycin prodrugs J. Med. Chem. 56 2013 4104 4115
165. M.P. McCrane, M.A. Hutchinson, O. Ad, and S.E. Rokita Oxidative quenching of quinone methide adducts reveals transient products of reversible alkylation in duplex DNA Chem. Res. Toxicol. 27 2014 1282 1293
166. T.C. Johnstone, S.M. Alexander, J.J. Wilson, and S.J. Lippard Oxidative halogenation of cisplatin and carboplatin: synthesis, spectroscopy, and crystal and molecular structures of Pt(IV) prodrugs Dalton Trans. 44 2015 119 129
167. Y.R. Zheng, K. Suntharalingam, T.C. Johnstone, H. Yoo, W. Lin, J.G. Brooks, and S.J. Lippard Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery J. Am. Chem. Soc. 136 2014 8790 8798
168. V. Novohradsky, L. Zerzankova, J. Stepankova, O. Vrana, R. Raveendran, D. Gibson, J. Kasparkova, and V. Brabec Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands J. Inorg. Biochem. 140 2014 72 79
169. W. Neumann, B.C. Crews, M.B. Sarosi, C.M. Daniel, K. Ghebreselasie, M.S. Scholz, L.J. Marnett, and E. Hey-Hawkins Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance ChemMedChem 10 2015 183 192
170. W. Neumann, B.C. Crews, L.J. Marnett, and E. Hey-Hawkins Conjugates of cisplatin and cyclooxygenase inhibitors as potent antitumor agents overcoming cisplatin resistance ChemMedChem 9 2014 1150 1153
171. I. Zanellato, I. Bonarrigo, D. Colangelo, E. Gabano, M. Ravera, M. Alessio, and D. Osella Biological activity of a series of cisplatin-based aliphatic bis(carboxylato) Pt(IV) prodrugs: how long the organic chain should be? J. Inorg. Biochem. 140 2014 219 227
172. H. Xiao, G.T. Noble, J.F. Stefanick, R. Qi, T. Kiziltepe, X. Jing, and B. Bilgicer Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo J. Control. Release 2013
173. R.K. Pathak, S. Marrache, J.H. Choi, T.B. Berding, and S. Dhar The prodrug platin-A: simultaneous release of cisplatin and aspirin Angew. Chem. 53 2014 1963 1967
174. Y. Min, J. Li, F. Liu, E.K. Yeow, and B. Xing Near-infrared light-mediated photoactivation of a platinum antitumor prodrug and simultaneous cellular apoptosis imaging by upconversion-luminescent nanoparticles Angew. Chem. 53 2014 1012 1016
175. X.Z. Yang, X.J. Du, Y. Liu, Y.H. Zhu, Y.Z. Liu, Y.P. Li, and J. Wang Rational design of polyion complex nanoparticles to overcome cisplatin resistance in cancer therapy Adv. Mater. 26 2014 931 936
176. Y. Yang, Y.M. Zhang, Y. Chen, J.T. Chen, and Y. Liu Targeted polysaccharide nanoparticle for adamplatin prodrug delivery J. Med. Chem. 56 2013 9725 9736
177. S.L. Yoong, B.S. Wong, Q.L. Zhou, C.F. Chin, J. Li, T. Venkatesan, H.K. Ho, V. Yu, W.H. Ang, and G. Pastorin Enhanced cytotoxicity to cancer cells by mitochondria-targeting MWCNTs containing platinum(IV) prodrug of cisplatin Biomaterials 35 2014 748 759
178. J. Hou, J. Shang, C. Jiao, P. Jiang, H. Xiao, L. Luo, and T. Liu A core cross-linked polymeric micellar platium(IV) prodrug with enhanced anticancer efficiency Macromol. Biosci. 13 2013 954 965
179. T.C. Johnstone, J.J. Wilson, and S.J. Lippard Monofunctional and higher-valent platinum anticancer agents Inorg. Chem. 52 2013 12234 12249
180. Y. Zhao, J.A. Woods, N.J. Farrer, K.S. Robinson, J. Pracharova, J. Kasparkova, O. Novakova, H. Li, L. Salassa, A.M. Pizarro, G.J. Clarkson, L. Song, V. Brabec, and P.J. Sadler Diazido mixed-amine platinum(IV) anticancer complexes activatable by visible-light form novel DNA adducts Chemistry 19 2013 9578 9591
181. Y. Mi, J. Zhao, and S.S. Feng Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer J. Control. Release 169 2013 185 192
182. S.M. Valiahdi, A.E. Egger, W. Miklos, U. Jungwirth, K. Meelich, P. Nock, W. Berger, C.G. Hartinger, M. Galanski, M.A. Jakupec, and B.K. Keppler Influence of extracellular pH on the cytotoxicity, cellular accumulation, and DNA interaction of novel pH-sensitive 2-aminoalcoholatoplatinum(II) complexes J. Biol. Inorg. Chem. 18 2013 249 260
183. K. Fujimoto, Y.K. Takematsu, A. Shigeno, M. Furusawa, and T. Sakamoto Short oligonucleotide prodrug having 5-fluoro and 5-iodouracil inhibits the proliferation of cancer cells in a photo-responsive manner Bioorg. Med. Chem. Lett. 24 2014 3736 3738
184. J.T. Weiss, J.C. Dawson, C. Fraser, W. Rybski, C. Torres-Sanchez, M. Bradley, E.E. Patton, N.O. Carragher, and A. Unciti-Broceta Development and bioorthogonal activation of palladium-labile prodrugs of gemcitabine J. Med. Chem. 57 2014 5395 5404
185. S.X. Cui, H.L. Zhang, W.F. Xu, and X.J. Qu 13F-1, a novel 5-fluorouracil prodrug containing an Asn-Gly-Arg (NO2) COOCH3 tripeptide, inhibits human colonic carcinoma growth by targeting Aminopeptidase N (APN/CD13) Eur. J. Pharmacol. 734 2014 50 59
186. J. Baraniak, A. Pietkiewicz, R. Kaczmarek, E. Radzikowska, K. Kulik, K. Krolewska, M. Cieslak, A. Krakowiak, and B. Nawrot N-Acyl-phosphoramidates as potential novel form of gemcitabine prodrugs Bioorg. Med. Chem. 22 2014 2133 2140
187. M. Slusarczyk, M.H. Lopez, J. Balzarini, M. Mason, W.G. Jiang, S. Blagden, E. Thompson, E. Ghazaly, and C. McGuigan Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development J. Med. Chem. 57 2014 1531 1542
188. J. Zhao, R. Zhou, X. Fu, W. Ren, L. Ma, R. Li, Y. Zhao, and L. Guo Cell-penetrable lysine dendrimers for anti-cancer drug delivery: synthesis and preliminary biological evaluation Arch. Pharm. 347 2014 469 477
189. F. Bekkara-Aounallah, A. Ambike, R. Gref, P. Couvreur, and V. Rosilio Interfacial behavior of PEGylated lipids and their effect on the stability of squalenoyl-drug nanoassemblies Int. J. Pharm. 471 2014 75 82
190. Z. Daman, S. Ostad, M. Amini, and K. Gilani Preparation, optimization and in vitro characterization of stearoyl-gemcitabine polymeric micelles: a comparison with its self-assembled nanoparticles Int. J. Pharm. 468 2014 142 151
191. S. Kim, D.J. Lee, D.S. Kwag, U.Y. Lee, Y.S. Youn, and E.S. Lee Acid pH-activated glycol chitosan/fullerene nanogels for efficient tumor therapy Carbohydr. Polym. 101 2014 692 698
192. N. Ueki, S. Lee, N.S. Sampson, and M.J. Hayman Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease Nat. Commun. 4 2013 2735
193. D.T. Bui, J. Nicolas, A. Maksimenko, D. Desmaele, and P. Couvreur Multifunctional squalene-based prodrug nanoparticles for targeted cancer therapy Chem. Commun. 50 2014 5336 5338
194. Y. Jin, F. Yang, and L. Du Nanoassemblies containing a fluorouracil/zidovudine glyceryl prodrug with phospholipase A2-triggered drug release for cancer treatment Colloids Surf. B: Biointerfaces 112 2013 421 428
195. I. Tsybulskaya, T. Kulak, A. Baranovsky, M. Golubeva, B. Kuzmitsky, and E. Kalinichenko Synthesis and in vitro cytostatic activity of 1,2- and 1,3-diacylglycerophosphates of clofarabine Bioorg. Med. Chem. 21 2013 5414 5419
196. B.S. Lee, Y.W. Cho, G.C. Kim, H. Lee do, C.J. Kim, H.S. Kil, D.Y. Chi, Y. Byun, S.H. Yuk, K. Kim, I.S. Kim, I.C. Kwon, and S.Y. Kim Induced phenotype targeted therapy: radiation-induced apoptosis-targeted chemotherapy J. Natl. Cancer Inst. 107 2015
197. R. Soudy, C. Chen, and K. Kaur Novel peptide-doxorubucin conjugates for targeting breast cancer cells including the multidrug resistant cells J. Med. Chem. 56 2013 7564 7573
198. L. Tang, R. Duan, Y.J. Zhong, R.A. Firestone, Y.P. Hong, J.G. Li, Y.C. Xin, H.L. Wu, and Y. Li Synthesis, identification and in vivo studies of tumor-targeting agent peptide doxorubicin (PDOX) to treat peritoneal carcinomatosis of gastric cancer with similar efficacy but reduced toxicity Mol. Cancer 13 2014 44
199. N. Tarasenko, S.M. Cutts, D.R. Phillips, G. Berkovitch-Luria, E. Bardugo-Nissim, M. Weitman, A. Nudelman, and A. Rephaeli A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo Biochem. Pharmacol. 88 2014 158 168
200. N. Duhem, F. Danhier, V. Pourcelle, J.M. Schumers, O. Bertrand, C.S. Leduff, S. Hoeppener, U.S. Schubert, J.F. Gohy, J. Marchand-Brynaert, and V. Preat Self-assembling doxorubicin-tocopherol succinate prodrug as a new drug delivery system: synthesis, characterization, and in vitro and in vivo anticancer activity Bioconjug. Chem. 25 2014 72 81
201. O.P. Oommen, J. Garousi, M. Sloff, and O.P. Varghese Tailored doxorubicin-hyaluronan conjugate as a potent anticancer glyco-drug: an alternative to prodrug approach Macromol. Biosci. 14 2014 327 333
202. Q. Wang, Y.J. Zhong, J.P. Yuan, L.H. Shao, J. Zhang, L. Tang, S.P. Liu, Y.P. Hong, R.A. Firestone, and Y. Li Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study J. Transl. Med. 11 2013 192
203. L.E. Samuelson, R.L. Scherer, L.M. Matrisian, J.O. McIntyre, and D.J. Bornhop Synthesis and in vitro efficacy of MMP9-activated NanoDendrons Mol. Pharm. 10 2013 3164 3174
204. X. Guo, C. Shi, J. Wang, S. Di, and S. Zhou pH-triggered intracellular release from actively targeting polymer micelles Biomaterials 34 2013 4544 4554
205. A. Nasrolahi Shirazi, R. Tiwari, B.S. Chhikara, D. Mandal, and K. Parang Design and biological evaluation of cell-penetrating peptide-doxorubicin conjugates as prodrugs Mol. Pharm. 10 2013 488 499
206. A.W. Girotti, and G. Minotti Development of a tumor-specific photoactivatable doxorubicin prodrug Photochem. Photobiol. 89 2013 1009 1010
207. Y. Wang, H. Wang, Y. Chen, X. Liu, Q. Jin, and J. Ji pH and hydrogen peroxide dual responsive supramolecular prodrug system for controlled release of bioactive molecules Colloids Surf. B: Biointerfaces 121 2014 189 195
208. J. Ding, D. Li, X. Zhuang, and X. Chen Self-assemblies of pH-activatable PEGylated multiarm poly(lactic acid-co-glycolic acid)-doxorubicin prodrugs with improved long-term antitumor efficacies Macromol. Biosci. 13 2013 1300 1307
209. C. Du, D. Deng, L. Shan, S. Wan, J. Cao, J. Tian, S. Achilefu, and Y. Gu A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery Biomaterials 34 2013 3087 3097
210. V. Shanmugam, Y.H. Chien, Y.S. Cheng, T.Y. Liu, C.C. Huang, C.H. Su, Y.S. Chen, U. Kumar, H.F. Hsu, and C.S. Yeh Oligonucleotides-assembled Au nanorod-assisted cancer photothermal ablation and combination chemotherapy with targeted dual-drug delivery of Doxorubicin and Cisplatin prodrug ACS Appl. Mater. Interfaces 6 2014 4382 4393
211. X. Zhang, K. Achazi, D. Steinhilber, F. Kratz, J. Dernedde, and R. Haag A facile approach for dual-responsive prodrug nanogels based on dendritic polyglycerols with minimal leaching J. Control. Release 174 2014 209 216
212. S. Bhuniya, S. Maiti, E.J. Kim, H. Lee, J.L. Sessler, K.S. Hong, and J.S. Kim An activatable theranostic for targeted cancer therapy and imaging Angew. Chem. 53 2014 4469 4474
213. D.V. Santi, E.L. Schneider, and G.W. Ashley Macromolecular prodrug that provides the irinotecan (CPT-11) active-metabolite SN-38 with ultralong half-life, low C(max), and low glucuronide formation J. Med. Chem. 57 2014 2303 2314
214. Z. Xu, W. Zheng, and Z. Yin Synthesis and optimization of a bifunctional hyaluronan-based camptothecin prodrug Arch. Pharm. 347 2014 240 246
215. M.S. Christodoulou, F. Zunino, V. Zuco, S. Borrelli, D. Comi, G. Fontana, M. Martinelli, J.B. Lorens, L. Evensen, M. Sironi, S. Pieraccini, L. Dalla Via, O.M. Gia, and D. Passarella Camptothecin-7-yl-methanthiole: semisynthesis and biological evaluation ChemMedChem 7 2012 2134 2143
216. W.A. Henne, S.A. Kularatne, J. Hakenjos, J.D. Carron, and K.L. Henne Synthesis and activity of a folate targeted monodisperse PEG camptothecin conjugate Bioorg. Med. Chem. Lett. 23 2013 5810 5813
217. J. Wang, X. Sun, W. Mao, W. Sun, J. Tang, M. Sui, Y. Shen, and Z. Gu Tumor redox heterogeneity-responsive prodrug nanocapsules for cancer chemotherapy Adv. Mater. 25 2013 3670 3676
218. Z. Xu, D. Wang, S. Xu, X. Liu, X. Zhang, and H. Zhang Preparation of a camptothecin prodrug with glutathione-responsive disulfide linker for anticancer drug delivery Chem. Asian. J. 9 2014 199 205
219. S. McRae Page, M. Martorella, S. Parelkar, I. Kosif, and T. Emrick Disulfide cross-linked phosphorylcholine micelles for triggered release of camptothecin Mol. Pharm. 10 2013 2684 2692
220. Q. Wu, F. Du, Y. Luo, W. Lu, J. Huang, J. Yu, and S. Liu Poly(ethylene glycol) shell-sheddable nanomicelle prodrug of camptothecin with enhanced cellular uptake Colloids Surf. B: Biointerfaces 105 2013 294 302
221. Q. Tang, B. Cao, and G. Cheng Co-delivery of small interfering RNA using a camptothecin prodrug as the carrier Chem. Commun. 50 2014 1323 1325
222. A. Satsangi, S.S. Roy, R.K. Satsangi, R.K. Vadlamudi, and J.L. Ong Design of a paclitaxel prodrug conjugate for active targeting of an enzyme upregulated in breast cancer cells Mol. Pharm. 11 2014 1906 1918
223. S. Mura, F. Zouhiri, S. Lerondel, A. Maksimenko, J. Mougin, C. Gueutin, D. Brambilla, J. Caron, E. Sliwinski, A. Lepape, D. Desmaele, and P. Couvreur Novel isoprenoyl nanoassembled prodrug for paclitaxel delivery Bioconjug. Chem. 24 2013 1840 1849
224. S. Arpicco, B. Stella, O. Schiavon, P. Milla, D. Zonari, and L. Cattel Preparation and characterization of novel poly(ethylene glycol) paclitaxel derivatives Int. J. Pharm. 454 2013 653 659
225. L. Yuan, W. Chen, J. Hu, J.Z. Zhang, and D. Yang Mechanistic study of the covalent loading of paclitaxel via disulfide linkers for controlled drug release Langmuir 29 2013 734 743
226. J. Caron, A. Maksimenko, S. Wack, E. Lepeltier, C. Bourgaux, E. Morvan, K. Leblanc, P. Couvreur, and D. Desmaele Improving the antitumor activity of squalenoyl-paclitaxel conjugate nanoassemblies by manipulating the linker between paclitaxel and squalene Adv. Healthcare Mater. 2 2013 172 185
227. A.R. Wohl, A.R. Michel, S. Kalscheuer, C.W. Macosko, J. Panyam, and T.R. Hoye Silicate esters of paclitaxel and docetaxel: synthesis, hydrophobicity, hydrolytic stability, cytotoxicity, and prodrug potential J. Med. Chem. 57 2014 2368 2379
228. N. Goodarzi, M.H. Ghahremani, M. Amini, F. Atyabi, S.N. Ostad, N. Shabani Ravari, N. Nateghian, and R. Dinarvand CD44-targeted docetaxel conjugate for cancer cells and cancer stem-like cells: a novel hyaluronic acid-based drug delivery system Chem. Biol. Drug Des. 83 2014 741 752
229. C. Xie, J. Chang, X.D. Hao, J.M. Yu, H.R. Liu, and X. Sun Mitochondrial-targeted prodrug cancer therapy using a rhodamine B labeled fluorinated docetaxel Eur. J. Pharm. Biopharm. 85 2013 541 549
230. N.R. Kuznetsova, E.V. Svirshchevskaya, N.S. Sitnikov, L. Abodo, H. Sutorius, J. Zapke, J. Velder, P. Thomopoulou, H. Oschkinat, A. Prokop, H.G. Schmalz, A.Y. Fedorov, and E.L. Vodovozova Lipophilic prodrugs of a triazole-containing colchicine analogue in liposomes: biological effects on human tumor cells Bioorg. Khim. 39 2013 609 618
231. S. Kambhampati, R.A. Rajewski, M. Tanol, I. Haque, A. Das, S. Banerjee, S. Jha, D. Burns, E. Borrego-Diaz, P.J. Van Veldhuizen, and S.K. Banerjee A second-generation 2-Methoxyestradiol prodrug is effective against Barrett's adenocarcinoma in a mouse xenograft model Mol. Cancer Ther. 12 2013 255 263
232. M. Bio, P. Rajaputra, G. Nkepang, and Y. You Far-red light activatable, multifunctional prodrug for fluorescence optical imaging and combinational treatment J. Med. Chem. 57 2014 3401 3409
233. A. dos Santos Edos, E. Hamel, R. Bai, J.C. Burnett, C.S. Tozatti, D. Bogo, R.T. Perdomo, A.M. Antunes, M.M. Marques, F. Matos Mde, and D.P. de Lima Synthesis and evaluation of diaryl sulfides and diaryl selenide compounds for antitubulin and cytotoxic activity Bioorg. Med. Chem. Lett. 23 2013 4669 4673
234. A. Ghinet, A. Tourteau, B. Rigo, V. Stocker, M. Leman, A. Farce, J. Dubois, and P. Gautret Synthesis and biological evaluation of fluoro analogues of antimitotic phenstatin Bioorg. Med. Chem. 21 2013 2932 2940
235. J.F. Marquez Ruiz, K. Kedziora, M. Pigott, B. Keogh, H. Windle, J. Gavin, D.P. Kelleher, and J.F. Gilmer A nitrophenyl-based prodrug type for colorectal targeting of prednisolone, budesonide and celecoxib Bioorg. Med. Chem. Lett. 23 2013 1693 1698
236. S. Prijic, J. Scancar, R. Romih, M. Cemazar, V.B. Bregar, A. Znidarsic, and G. Sersa Increased cellular uptake of biocompatible superparamagnetic iron oxide nanoparticles into malignant cells by an external magnetic field J. Membr. Biol. 236 2010 167 179
237. A. Nel, T. Xia, L. Madler, and N. Li Toxic potential of materials at the nanolevel Science 311 2006 622 627
238. M.W. Wilson, R.K. Kerlan Jr., N.A. Fidelman, A.P. Venook, J.M. LaBerge, J. Koda, and R.L. Gordon Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/ conventional angiography suite-initial experience with four patients Radiology 230 2004 287 293
239. R.C. Semelka, and T.K.G. Helmberger Contrast Agents for MR Imaging of the Liver Radiology 218 2001 27 38
240. C. Sun, O. Veiseh, J. Gunn, C. Fang, S. Hansen, D. Lee, R. Sze, R.G. Ellenbogen, J. Olson, and M. Zhang In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes Small 4 2008 372 379
241. M. Licciardi, C. Scialabba, G. Cavallaro, C. Sangregorio, E. Fantechi, and G. Giammona Cell uptake enhancement of folate targeted polymer coated magnetic nanoparticles J. Biomed. Nanotechnol. 9 2013 949 964
242. H. Yoo, S.K. Moon, T. Hwang, Y.S. Kim, J.H. Kim, S.W. Choi, and J.H. Kim Multifunctional magnetic nanoparticles modified with polyethylenimine and folic acid for biomedical theranostics Langmuir 29 2013 5962 5967
243. Q.L. Jiang, S.W. Zheng, R.Y. Hong, S.M. Deng, L. Guo, R.L. Hu, B. Gao, M. Huang, L.F. Cheng, G.H. Liu, and Y.Q. Wang Folic acid-conjugated Fe3O4 magnetic nanoparticles for hyperthermia and MRI in vitro and in vivo Appl. Surf. Sci. 307 2014 224 233
244. M. Jang, Y.I. Yoon, Y.S. Kwon, T.J. Yoon, H.J. Lee, S.I. Hwang, B.L. Yun, and S.M. Kim Trastuzumab-conjugated liposome-coated fluorescent magnetic nanoparticles to target breast cancer Korean J. Radiol. 15 2014 411 422
245. H.M. Yang, C.W. Park, M.A. Woo, M.I. Kim, Y.M. Jo, H.G. Park, and J.D. Kim HER2/neu antibody conjugated poly(amino acid)-coated iron oxide nanoparticles for breast cancer MR imaging Biomacromolecules 11 2010 2866 2872
246. F. Shamsipour, A.H. Zarnani, R. Ghods, M. Chamankhah, F. Forouzesh, S. Vafaei, A.A. Bayat, M.M. Akhondi, M. Ali Oghabian, and M. Jeddi-Tehrani Conjugation of Monoclonal Antibodies to Super Paramagnetic Iron Oxide Nanoparticles for Detection of her2/neu Antigen on Breast Cancer Cell Lines Avicenna J. Med. Biotechnol. 1 2009 27 31
247. L. Yang, H. Mao, Y.A. Wang, Z. Cao, X. Peng, X. Wang, H. Duan, C. Ni, Q. Yuan, G. Adams, M.Q. Smith, W.C. Wood, X. Gao, and S. Nie Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging Small 5 2009 235 243
248. A.A. Bharde, R. Palankar, C. Fritsch, A. Klaver, J.S. Kanger, T.M. Jovin, and D.J. Arndt-Jovin Magnetic nanoparticles as mediators of ligand-free activation of EGFR signaling PLoS One 8 2013 e68879
249. C.W. Lin, K.C. Wei, S.S. Liao, C.Y. Huang, C.L. Sun, P.J. Wu, Y.J. Lu, H.W. Yang, and C.C. Ma A reusable magnetic graphene oxide-modified biosensor for vascular endothelial growth factor detection in cancer diagnosis Biosens. Bioelectron. 67 2015 431 437
250. W.J. Hsieh, C.J. Liang, J.J. Chieh, S.H. Wang, I.R. Lai, J.H. Chen, F.H. Chang, W.K. Tseng, S.Y. Yang, C.C. Wu, and Y.L. Chen In vivo tumor targeting and imaging with anti-vascular endothelial growth factor antibody-conjugated dextran-coated iron oxide nanoparticles Int. J. Nanomedicine 7 2012 2833 2842
251. S. Wu, N. Duan, Z. Wang, and H. Wang Aptamer-functionalized magnetic nanoparticle-based bioassay for the detection of ochratoxin A using upconversion nanoparticles as labels Analyst 136 2011 2306 2314
252. A. Aravind, R. Nair, S. Raveendran, S. Veeranarayanan, Y. Nagaoka, T. Fukuda, T. Hasumura, H. Morimoto, Y. Yoshida, T. Maekawa, and D. Sakthi Kumar Aptamer conjugated paclitaxel and magnetic fluid loaded fluorescently tagged PLGA nanoparticles for targeted cancer therapy J. Magn. Magn. Mater. 344 2013 116 123
253. C. Fang, O. Veiseh, F. Kievit, N. Bhattarai, F. Wang, Z. Stephen, C. Li, D. Lee, R.G. Ellenbogen, and M. Zhang Functionalization of iron oxide magnetic nanoparticles with targeting ligands: their physicochemical properties and in vivo behavior Nanomedicine 5 2010 1357 1369
254. A. Jafari, M. Salouti, S.F. Shayesteh, Z. Heidari, A.B. Rajabi, K. Boustani, and A. Nahardani Synthesis and characterization of Bombesin-superparamagnetic iron oxide nanoparticles as a targeted contrast agent for imaging of breast cancer using MRI Nanotechnology 26 2015 075101
255. A.L. Martin, J.L. Hickey, A.L. Ablack, J.D. Lewis, L.G. Luyt, and E.R. Gillies Synthesis of bombesin-functionalized iron oxide nanoparticles and their specific uptake in prostate cancer cells J. Nanoparticle Res. 12 2009 1599 1608
256. J.D. Obayemi, S. Dozie-Nwachukwu, Y. Danyuo, O.S. Odusanya, N. Anuku, K. Malatesta, and W.O. Soboyejo Biosynthesis and the conjugation of magnetite nanoparticles with luteinizing hormone releasing hormone (LHRH) Mater. Sci. Eng. C 46 2015 482 496
257. C. Leuschner, C.S. Kumar, W. Hansel, W. Soboyejo, J. Zhou, and J. Hormes LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases Breast Cancer Res. Treat. 99 2006 163 176
258. M. Babic, D. Horak, M. Trchova, P. Jendelova, K. Glogarova, P. Lesny, V. Herynek, M. Hajek, and E. Sykova Poly(L-lysine)-modified iron oxide nanoparticles for stem cell labeling Bioconjug. Chem. 19 2008 740 750
259. M. Kumar, Z. Medarova, P. Pantazopoulos, G. Dai, and A. Moore Novel membrane-permeable contrast agent for brain tumor detection by MRI Magn. Reson. Med. 63 2010 617 624
260. Z. Medarova, M. Kumar, S.W. Ng, and A. Moore Development and application of a dual-purpose nanoparticle platform for delivery and imaging of siRNA in tumors Methods Mol. Biol. 555 2009 1 13
261. M. Lewin, N. Carlesso, C.H. Tung, X.W. Tang, D. Cory, D.T. Scadden, and R. Weissleder Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells Nat. Biotechnol. 18 2000 410 414
262. J. Lin, Y. Li, Y. Li, H. Wu, F. Yu, S. Zhou, L. Xie, F. Luo, C. Lin, and Z. Hou Drug/Dye-Loaded, Multifunctional PEG-Chitosan-Iron Oxide Nanocomposites for Methotraxate Synergistically Self-Targeted Cancer Therapy and Dual Model Imaging ACS Appl. Mater. Interfaces 7 2015 11908 11920
263. S.M. Cassim, A.J. Giustini, I. Baker, and P.J. Hoopes Development of Novel Magnetic Nanoparticles for Hyperthermia Cancer Therapy, Proceedings of SPIE-the International Society for Opt. Eng. 7901 2011 790115
264. S. Purushotham, and R.V. Ramanujan Thermoresponsive magnetic composite nanomaterials for multimodal cancer therapy Acta Biomater. 6 2010 502 510
265. C.S. Kumar, and F. Mohammad Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery Adv. Drug Deliv. Rev. 63 2011 789 808
266. J.E. Wong, A. Krishnakumar Gaharwar, D. Müller-Schulte, D. Bahadur, and W. Richtering Layer-by-layer assembly of a magnetic nanoparticle shell on a thermoresponsive microgel core J. Magn. Magn. Mater. 311 2007 219 223
267. N.S. Satarkar, and J.Z. Hilt Magnetic hydrogel nanocomposites for remote controlled pulsatile drug release J. Control. Release 130 2008 246 251
268. A.M. Derfus, v.M. Geoffrey, T.J. Harris, T. Duza, K.S. Vecchio, E. Ruoslahti, and S.N. Bhatia Remotely Triggered Release from Magnetic Nanoparticles Adv. Mater. vol. 19 2007 3932 3936
269. L. Liu, S. Chang, J. Sun, S. Zhu, M. Yin, Y. Zhu, Z. Wang, and R.X. Xu Ultrasound-mediated destruction of paclitaxel and oxygen loaded lipid microbubbles for combination therapy in ovarian cancer xenografts Cancer Lett. 361 2015 147 154
270. Z. Deng, F. Yan, Q. Jin, F. Li, J. Wu, X. Liu, and H. Zheng Reversal of multidrug resistance phenotype in human breast cancer cells using doxorubicin-liposome-microbubble complexes assisted by ultrasound J. Control. Release 174 2014 109 116
271. S. Ibsen, C.E. Schutt, and S. Esener Microbubble-mediated ultrasound therapy: a review of its potential in cancer treatment Drug Des. Devel. Ther. 7 2013 375 388
272. B.P. Timko, T. Dvir, and D.S. Kohane Remotely triggerable drug delivery systems Adv. Mater. 22 2010 4925 4943
273. Y. Ikeda-Dantsuji, L.B. Feril Jr., K. Tachibana, K. Ogawa, H. Endo, Y. Harada, R. Suzuki, and K. Maruyama Synergistic effect of ultrasound and antibiotics against Chlamydia trachomatis-infected human epithelial cells in vitro Ultrason. Sonochem. 18 2011 425 430
274. N. Rapoport, Z. Gao, and A. Kennedy Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy J. Natl. Cancer Inst. 99 2007 1095 1106
275. L. Solorio, and A.A. Exner Applications of ultrasound for image-guided drug delivery in cancer chemotherapy Ther. Deliv. 4 2013 785 789
276. Y. Zhou Ultrasound-mediated drug/gene delivery in solid tumor treatment J. Healthc. Eng. 4 2013 223 254
277. C.M. Panje, D.S. Wang, and J.K. Willmann Ultrasound and microbubble-mediated gene delivery in cancer: progress and perspectives Investig. Radiol. 48 2013 755 769
278. M.R. Dreher, W. Liu, C.R. Michelich, M.W. Dewhirst, F. Yuan, and A. Chilkoti Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers J. Natl. Cancer Inst. 98 2006 335 344
279. G. Kong, R.D. Braun, and M.W. Dewhirst Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size Cancer Res. 60 2000 4440 4445
280. G. Kong, G. Anyarambhatla, W.P. Petros, R.D. Braun, O.M. Colvin, D. Needham, and M.W. Dewhirst Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release Cancer Res. 60 2000 6950 6957
281. T. Nishita Heat-sensitive liposomes containing cisplatin and localized hyperthermia in treatment of murine tumor Osaka City Med. J. 44 1998 73 83
282. J.N. Weinstein, R.L. Magin, R.L. Cysyk, and D.S. Zaharko Treatment of solid L1210 murine tumors with local hyperthermia and temperature-sensitive liposomes containing methotrexate Cancer Res. 40 1980 1388 1395
283. M.L. Hauck, S.M. LaRue, W.P. Petros, J.M. Poulson, D. Yu, I. Spasojevic, A.F. Pruitt, A. Klein, B. Case, D.E. Thrall, D. Needham, and M.W. Dewhirst Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors Clin. Cancer Res. 12 2006 4004 4010
284. M.H. Gaber, N.Z. Wu, K. Hong, S.K. Huang, M.W. Dewhirst, and D. Papahadjopoulos Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks Int. J. Radiat. Oncol. Biol. Phys. 36 1996 1177 1187
285. S. Dromi, V. Frenkel, A. Luk, B. Traughber, M. Angstadt, M. Bur, J. Poff, J. Xie, S.K. Libutti, K.C. Li, and B.J. Wood Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect Clin. Cancer Res. 13 2007 2722 2727
286. V. Frenkel Ultrasound mediated delivery of drugs and genes to solid tumors Adv. Drug Deliv. Rev. 60 2008 1193 1208
287. P. Paparel, L. Curiel, S. Chesnais, R. Ecochard, J.Y. Chapelon, and A. Gelet Synergistic inhibitory effect of high-intensity focused ultrasound combined with chemotherapy on Dunning adenocarcinoma BJU Int. 95 2005 881 885
288. C.X. Deng, F. Sieling, H. Pan, and J. Cui Ultrasound-induced cell membrane porosity Ultrasound Med. Biol. 30 2004 519 526
289. F. Prat, J.Y. Chapelon, F.A. el Fadil, Y. Theillere, T. Ponchon, and D. Cathignol In vivo effects of cavitation alone or in combination with chemotherapy in a peritoneal carcinomatosis in the rat Br. J. Cancer 68 1993 13 17
290. P. Riesz, and T. Kondo Free radical formation induced by ultrasound and its biological implications Free Radic. Biol. Med. 13 1992 247 270
291. D. Bommannan, G.K. Menon, H. Okuyama, P.M. Elias, and R.H. Guy Sonophoresis. II. Examination of the mechanism(s) of ultrasound-enhanced transdermal drug delivery Pharm. Res. 9 1992 1043 1047
292. A. Yudina, M. Lepetit-Coiffe, and C.T. Moonen Evaluation of the temporal window for drug delivery following ultrasound-mediated membrane permeability enhancement Mol. Imaging Biol. 13 2011 239 249
293. B.D. Meijering, L.J. Juffermans, A. van Wamel, R.H. Henning, I.S. Zuhorn, M. Emmer, A.M. Versteilen, W.J. Paulus, W.H. van Gilst, K. Kooiman, N. de Jong, R.J. Musters, L.E. Deelman, and O. Kamp Ultrasound and microbubble-targeted delivery of macromolecules is regulated by induction of endocytosis and pore formation Circ. Res. 104 2009 679 687
294. A. van Wamel, K. Kooiman, M. Emmer, F.J. ten Cate, M. Versluis, and N. de Jong Ultrasound microbubble induced endothelial cell permeability J. Control. Release 116 2006 e100 e102
295. M. Saito, O. Mazda, K.A. Takahashi, Y. Arai, T. Kishida, M. Shin-Ya, A. Inoue, H. Tonomura, K. Sakao, T. Morihara, J. Imanishi, M. Kawata, and T. Kubo Sonoporation mediated transduction of pDNA/siRNA into joint synovium in vivo J. Orthop. Res. 25 2007 1308 1316
296. A. Kheirolomoom, L.M. Mahakian, C.Y. Lai, H.A. Lindfors, J.W. Seo, E.E. Paoli, K.D. Watson, E.M. Haynam, E.S. Ingham, L. Xing, R.H. Cheng, A.D. Borowsky, R.D. Cardiff, and K.W. Ferrara Copper-doxorubicin as a nanoparticle cargo retains efficacy with minimal toxicity Mol. Pharm. 7 2010 1948 1958
297. N. Frulio, H. Trillaud, R. Deckers, S. Lepreux, C. Moonen, and B. Quesson Influence of ultrasound induced cavitation on magnetic resonance imaging contrast in the rat liver in the presence of macromolecular contrast agent Investig. Radiol. 45 2010 282 287
298. E.E. Paoli, D.E. Kruse, J.W. Seo, H. Zhang, A. Kheirolomoom, K.D. Watson, P. Chiu, H. Stahlberg, and K.W. Ferrara An optical and microPET assessment of thermally-sensitive liposome biodistribution in the Met-1 tumor model: Importance of formulation J. Control. Release 143 2010 13 22
299. S. Hernot, and A.L. Klibanov Microbubbles in ultrasound-triggered drug and gene delivery Adv. Drug Deliv. Rev. 60 2008 1153 1166
300. F. Guenther, C. von zur Muhlen, E.A. Ferrante, S. Grundmann, C. Bode, and A.L. Klibanov An ultrasound contrast agent targeted to P-selectin detects activated platelets at supra-arterial shear flow conditions Investig. Radiol. 45 2010 586 591
301. L.C. Phillips, A.L. Klibanov, B.R. Wamhoff, and J.A. Hossack Targeted gene transfection from microbubbles into vascular smooth muscle cells using focused, ultrasound-mediated delivery Ultrasound Med. Biol. 36 2010 1470 1480
302. A.V. Patil, J.J. Rychak, J.S. Allen, A.L. Klibanov, and J.A. Hossack Dual frequency method for simultaneous translation and real-time imaging of ultrasound contrast agents within large blood vessels Ultrasound Med. Biol. 35 2009 2021 2030
303. J.W. Xuan, M. Bygrave, F. Valiyeva, M. Moussa, J.I. Izawa, G.S. Bauman, A. Klibanov, F. Wang, N.M. Greenberg, and A. Fenster Molecular targeted enhanced ultrasound imaging of flk1 reveals diagnosis and prognosis potential in a genetically engineered mouse prostate cancer model Mol. Imaging 8 2009 209 220
304. M.R. Bohmer, A.L. Klibanov, K. Tiemann, C.S. Hall, H. Gruell, and O.C. Steinbach Ultrasound triggered image-guided drug delivery Eur. J. Radiol. 70 2009 242 253
305. J.C. Chappell, J. Song, C.W. Burke, A.L. Klibanov, and R.J. Price Targeted delivery of nanoparticles bearing fibroblast growth factor-2 by ultrasonic microbubble destruction for therapeutic arteriogenesis Small 4 2008 1769 1777
306. D. Hollander, and L.S. Adelman Eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan: muscle biopsy findings in 4 patients Neurology 41 1991 319 321
307. K. Ninomiya, T. Yamashita, S. Kawabata, and N. Shimizu Targeted and ultrasound-triggered drug delivery using liposomes co-modified with cancer cell-targeting aptamers and a thermosensitive polymer Ultrason. Sonochem. 21 2014 1482 1488
308. S. Mo, C.C. Coussios, L. Seymour, and R. Carlisle Ultrasound-enhanced drug delivery for cancer Expert Opin. Drug Deliv. 9 2012 1525 1538
309. D.L. Miller, N.B. Smith, M.R. Bailey, G.J. Czarnota, K. Hynynen, and I.R. Makin M. Bioeffects Committee of the American Institute of Ultrasound in, Overview of therapeutic ultrasound applications and safety considerations J. Ultrasound Med. 31 2012 623 634
310. V. Frenkel, R. Gurka, A. Liberzon, U. Shavit, and E. Kimmel Preliminary investigations of ultrasound induced acoustic streaming using particle image velocimetry Ultrasonics 39 2001 153 156
311. V. Frenkel, E. Kimmel, and Y. Iger Ultrasound-facilitated transport of silver chloride (AgCl) particles in fish skin J. Control. Release 68 2000 251 261
312. S. Eggen, S.M. Fagerland, Y. Morch, R. Hansen, K. Sovik, S. Berg, H. Furu, A.D. Bohn, M.B. Lilledahl, A. Angelsen, B. Angelsen, and C. de Lange Davies Ultrasound-enhanced drug delivery in prostate cancer xenografts by nanoparticles stabilizing microbubbles J. Control. Release 187 2014 39 49
313. C.K. Holland, and D.D. McPherson Echogenic Lipsomes for Targeted Drug Delivery Proceedings / IEEE International Symposium on Biomedical Imaging: from nano to macro IEEE International Symposium on Biomedical Imaging 2009 2009 755 758
314. K.W. Ferrara Driving delivery vehicles with ultrasound Adv. Drug Deliv. Rev. 60 2008 1097 1102
315. S.M. Stieger, C.F. Caskey, R.H. Adamson, S. Qin, F.R. Curry, E.R. Wisner, and K.W. Ferrara Enhancement of vascular permeability with low-frequency contrast-enhanced ultrasound in the chorioallantoic membrane model Radiology 243 2007 112 121
316. P.A. Dayton, S. Zhao, S.H. Bloch, P. Schumann, K. Penrose, T.O. Matsunaga, R. Zutshi, A. Doinikov, and K.W. Ferrara Application of ultrasound to selectively localize nanodroplets for targeted imaging and therapy Mol. Imaging 5 2006 160 174
317. P. Dayton, A. Klibanov, G. Brandenburger, and K. Ferrara Acoustic radiation force in vivo: a mechanism to assist targeting of microbubbles Ultrasound Med. Biol. 25 1999 1195 1201
318. A.F. Lum, M.A. Borden, P.A. Dayton, D.E. Kruse, S.I. Simon, and K.W. Ferrara Ultrasound radiation force enables targeted deposition of model drug carriers loaded on microbubbles J. Control. Release 111 2006 128 134
319. N. Rapoport, K.H. Nam, R. Gupta, Z. Gao, P. Mohan, A. Payne, N. Todd, X. Liu, T. Kim, J. Shea, C. Scaife, D.L. Parker, E.K. Jeong, and A.M. Kennedy Ultrasound-mediated tumor imaging and nanotherapy using drug loaded, block copolymer stabilized perfluorocarbon nanoemulsions J. Control. Release 153 2011 4 15
320. N. Rapoport, A.M. Kennedy, J.E. Shea, C.L. Scaife, and K.H. Nam Ultrasonic nanotherapy of pancreatic cancer: lessons from ultrasound imaging Mol. Pharm. 7 2010 22 31
321. N.Y. Rapoport, A.M. Kennedy, J.E. Shea, C.L. Scaife, and K.H. Nam Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions/microbubbles J. Control. Release 138 2009 268 276
322. N. Vykhodtseva, N. McDannold, and K. Hynynen Progress and problems in the application of focused ultrasound for blood-brain barrier disruption Ultrasonics 48 2008 279 296
323. N. McDannold, N. Vykhodtseva, and K. Hynynen Effects of acoustic parameters and ultrasound contrast agent dose on focused-ultrasound induced blood-brain barrier disruption Ultrasound Med. Biol. 34 2008 930 937
324. L.H. Treat, N. McDannold, N. Vykhodtseva, Y. Zhang, K. Tam, and K. Hynynen Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound Int. J. Cancer 121 2007 901 907
325. N. Vykhodtseva, N. McDannold, and K. Hynynen Induction of apoptosis in vivo in the rabbit brain with focused ultrasound and Optison Ultrasound Med. Biol. 32 2006 1923 1929
326. P. Lu, X.Q. Zhu, Z.L. Xu, Q. Zhou, J. Zhang, and F. Wu Increased infiltration of activated tumor-infiltrating lymphocytes after high intensity focused ultrasound ablation of human breast cancer Surgery 145 2009 286 293
327. Z. Hu, X.Y. Yang, Y. Liu, G.N. Sankin, E.C. Pua, M.A. Morse, H.K. Lyerly, T.M. Clay, and P. Zhong Investigation of HIFU-induced anti-tumor immunity in a murine tumor model J. Transl. Med. 5 2007 34
328. F. Wu, L. Zhou, and W.R. Chen Host antitumour immune responses to HIFU ablation Int. J. Hyperth. 23 2007 165 171
329. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2 2002 48 58
330. A. Marusyk, and K. Polyak Tumor heterogeneity: causes and consequences Biochim. Biophys. Acta 1805 2010 105 117
331. H. Zahreddine, and K.L. Borden Mechanisms and insights into drug resistance in cancer Front. Pharmacol. 4 2013 28
332. R.K. Vadlapatla, A.D. Vadlapudi, D. Pal, and A.K. Mitra Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes Curr. Pharm. Des. 19 2013 7126 7140
333. A.K. Wilson, J.R. Latham, and R.A. Steinbrecher Transformation-induced mutations in transgenic plants: analysis and biosafety implications Biotechnol. Genet. Eng. Rev. 23 2006 209 237
334. M.M. Gottesman Mechanisms of cancer drug resistance Annu. Rev. Med. 53 2002 615 627
335. C. International Transporter, K.M. Giacomini, S.M. Huang, D.J. Tweedie, L.Z. Benet, K.L. Brouwer, X. Chu, A. Dahlin, R. Evers, V. Fischer, K.M. Hillgren, K.A. Hoffmaster, T. Ishikawa, D. Keppler, R.B. Kim, C.A. Lee, M. Niemi, J.W. Polli, Y. Sugiyama, P.W. Swaan, J.A. Ware, S.H. Wright, S.W. Yee, M.J. Zamek-Gliszczynski, and L. Zhang Membrane transporters in drug development Nat. Rev. Drug Discov. 9 2010 215 236
336. S.V. Ambudkar, C. Kimchi-Sarfaty, Z.E. Sauna, and M.M. Gottesman P-glycoprotein: from genomics to mechanism Oncogene 22 2003 7468 7485
337. J.L. Biedler, and H. Riehm Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies Cancer Res. 30 1970 1174 1184
338. C.F. Higgins ABC transporters: from microorganisms to man Annu. Rev. Cell Biol. 8 1992 67 113
339. K.P. Locher, and E. Borths ABC transporter architecture and mechanism: implications from the crystal structures of BtuCD and BtuF FEBS Lett. 564 2004 264 268
340. Z. Wang, D. Pal, A. Patel, D. Kwatra, and A.K. Mitra Influence of overexpression of efflux proteins on the function and gene expression of endogenous peptide transporters in MDR-transfected MDCKII cell lines Int. J. Pharm. 441 2013 40 49
341. V. Khurana, M. Minocha, D. Pal, and A.K. Mitra Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors Drug Metabol. Drug Interact. 29 2014 179 190
342. R.K. Vadlapatla, D. Pal, A.D. Vadlapudi, and A.K. Mitra Ritonavir: a powerful boosting agent for overcoming drug resistance in cancer chemotherapy Cancer Sci. & Therapy. 6 11 2014 446 454
343. W.G. Harker, D. Bauer, B.B. Etiz, R.A. Newman, and B.I. Sikic Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission Cancer Res. 46 1986 2369 2373
344. M. Inaba, H. Kobayashi, Y. Sakurai, and R.K. Johnson Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia Cancer Res. 39 1979 2200 2203
345. R.F. Ozols, R.E. Cunnion, R.W. Klecker Jr., T.C. Hamilton, Y. Ostchega, J.E. Parrillo, and R.C. Young Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 5 1987 641 647
346. B. Jonsson, K. Nilsson, P. Nygren, and R. Larsson SDZ PSC-833-a novel potent in vitro chemosensitizer in multiple myeloma Anti-Cancer Drugs 3 1992 641 646
347. R. Pirker, D.J. FitzGerald, M. Raschack, Z. Frank, M.C. Willingham, and I. Pastan Enhancement of the activity of immunotoxins by analogues of verapamil Cancer Res. 49 1989 4791 4795
348. G. Giaccone, S.C. Linn, J. Welink, G. Catimel, H. Stieltjes, W.J. van der Vijgh, C. Eeltink, J.B. Vermorken, and H.M. Pinedo A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors Clin. Cancer Res. 3 1997 2005 2015
349. W.H. Wilson, C. Jamis-Dow, G. Bryant, F.M. Balis, R.W. Klecker, S.E. Bates, B.A. Chabner, S.M. Steinberg, D.R. Kohler, and R.E. Wittes Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 13 1995 1985 1994
350. B.L. Lum, and M.P. Gosland MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-Glycoprotein inhibitors Hematol. Oncol. Clin. North Am. 9 1995 319 336
351. A.H. Dantzig, R.L. Shepard, J. Cao, K.L. Law, W.J. Ehlhardt, T.M. Baughman, T.F. Bumol, and J.J. Starling Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979 Cancer Res. 56 1996 4171 4179
352. I.L. Dale, W. Tuffley, R. Callaghan, J.A. Holmes, K. Martin, M. Luscombe, P. Mistry, H. Ryder, A.J. Stewart, P. Charlton, P.R. Twentyman, and P. Bevan Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative Br. J. Cancer 78 1998 885 892
353. F. Hyafil, C. Vergely, P.D. Vignaud, and T. Grand-Perret In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative Cancer Res. 53 1993 4595 4602
354. A.H. Dantzig, K.L. Law, J. Cao, and J.J. Starling Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic Curr. Med. Chem. 8 2001 39 50
355. P. Ruff, D.A. Vorobiof, J.P. Jordaan, G.S. Demetriou, S.D. Moodley, A.L. Nosworthy, I.D. Werner, J. Raats, and L.J. Burgess A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen Cancer Chemother. Pharmacol. 64 2009 763 768
356. J.E. Lancet, M.R. Baer, G.E. Duran, A.F. List, R. Fielding, J.F. Marcelletti, P.S. Multani, and B.I. Sikic A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia Leuk. Res. 33 2009 1055 1061
357. F. Morschhauser, P.L. Zinzani, M. Burgess, L. Sloots, F. Bouafia, and C. Dumontet Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma Leuk. Lymphoma 48 2007 708 715
358. A. Sandler, M. Gordon, D.P. De Alwis, I. Pouliquen, L. Green, P. Marder, A. Chaudhary, K. Fife, L. Battiato, C. Sweeney, C. Jordan, M. Burgess, and C.A. Slapak A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy Clin. Cancer Res. 10 2004 3265 3272
359. R.J. Kathawala, Y.J. Wang, S. Shukla, Y.K. Zhang, S. Alqahtani, A. Kaddoumi, S.V. Ambudkar, C.R. Ashby Jr., and Z.S. Chen ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel Chin. J. Cancer 34 2015 115 120
360. W. Bardenheuer, K. Lehmberg, I. Rattmann, A. Brueckner, A. Schneider, U.R. Sorg, S. Seeber, T. Moritz, and M. Flasshove Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells Leukemia 19 2005 2281 2288
361. D. Sampath, J. Cortes, Z. Estrov, M. Du, Z. Shi, M. Andreeff, V. Gandhi, and W. Plunkett Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial Blood 107 2006 2517 2524